Market Size of Europe Oral Anti-Diabetic Drug Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 7.36 Billion |
| Market Size (2029) | USD 8.70 Billion |
| CAGR (2024 - 2029) | 3.40 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Oral Anti-Diabetic Drug Market Analysis
The Europe Oral Anti-Diabetic Drug Market size is estimated at USD 7.36 billion in 2024, and is expected to reach USD 8.70 billion by 2029, growing at a CAGR of 3.40% during the forecast period (2024-2029).
The COVID-19 epidemic significantly influenced the European Diabetes Medicines Market. As people with diabetes already have weakened immune systems, COVID-19 causes those immune systems to deteriorate rapidly. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the makers of diabetes pharmaceuticals took special care to ensure that diabetic patients received their meds with the assistance of local governments. On their website, NovoNordisk stated that they "continue to provide our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses.
Pharmaceuticals known as diabetic medications were created to stabilize and regulate blood glucose levels in diabetics. Diabetes patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications. The estimated cost per hospital admission for type 2 diabetes patients with good glycemic control during the first wave of COVID-19 in Europe ranged from EUR 25,018 to EUR 57,244 for type 1 diabetes patients with poor glycemic control, reflecting a higher risk of intensive care, ventilator support, and a longer hospital stay. Those without diabetes were expected to pay EUR 16,993. For COVID-19 secondary care, 13.9 billion euros in direct costs were projected to be spent overall in Europe. Hence, diabetes treatment accounted for 23.5% of overall costs.
In recent years, diabetes prevalence has increased alarmingly throughout the European continent. Many health issues are related to diabetes. Diabetes patients need to make several adjustments throughout the day to keep their blood glucose levels within normal ranges. For example, they may need to administer more insulin or consume more carbohydrates.
As a result of the aforementioned variables, it is projected that the market under study will expand during the course of the investigation.
